NEW YORK — Deloitte plans to launch a data-mining system next month that it said would provide life-sciences organizations more access to the "front lines" of patient care and help them develop more personalized medicines based on clinical data more quickly and at a lower cost than before.
The company announced Wednesday the upcoming launch of PopulationMiner, a real-world data-analytics system for gleaning insights and relationships among drugs and diseases across broad patient populations over time and spanning several therapeutic and clinical areas. The system will draw on a large repository of clinical, financial and operational data stored in a warehouse that supports patient-outcome analysis, owned by Intermountain Healthcare.
"With the shift toward value-based, personalized care, it's key for life-sciences decision makers to have deep insights into complex, real-world populations," Deloitte Consulting principal and Deloitte Health Informatics general manager Brett Davis said. "PopulationMiner enables a better understanding of health and disease by supporting population stratification and advanced analytics based on disease type, stage and comorbid combinations. With a few clicks, this platform can provide an unprecedented level of nuanced insights from millions of patients, leveraging informatics and clinical expertise form Deloitte and Intermountain Healthcare."
PopulationMiner may allow for the identification of biomarkers using laboratory test results and rapid hypothesis generation and validation across a range of business functions, including drug development, drug safety, pharmacoepidemiology and health economics and outcomes research.
"PopulationMiner aims to provide organizations with an integrated comparative analytics platform so that they can discover opportunities to dramatically enhance the quality of care delivery while reducing costs," Deloitte Consulting principal Scott Kolesar said.